Melinta reports Phase III success for antibiotic
This article was originally published in Scrip
Connecticut-based Melinta Therapeutics says that a Phase III study of its lead product, the investigational fluoroquinalone antibiotic, delafloxacin IV has met its primary end point.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.